BioSpace News Archive

Meitheal Pharmaceuticals (“Meitheal”), a fully integrated generic injectables company today announced that the US Food and Drug Administration (FDA) has approved a new vial manufacturing line at majority shareholder, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.’s (NKF), Nanjing, China facility and further announced plans to expand manufacturing capacity.

Leadiant Biosciences, Inc. announced it is conducting the Registry Study of Revcovi® (elapegademase-lvlr) injection 1.6 mg/ml Treatment in Patients with Adenosine Deaminase Severe Combined Immune Deficiency (ADA-SCID).

Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health products, announced financial results for the third quarter and first nine months of fiscal year 2020, ended December 31, 2019.

Metactive Medical, Inc., a medical device company developing innovative products for peripheral vascular and neurovascular diseases, announced today that it has changed its name to Artio Medical, Inc. effective immediately. “The corporate name change marks an important milestone as we progr

Molex will showcase next-generation MedTech solutions and manufacturing capabilities from booth 3278 at the MD&M West 2020 Exhibition, February 11–13, 2020 at the Anaheim Convention Center.

LHC Group, Inc. announced details for the release of its results for the fourth quarter and year ended December 31, 2019.

Overall 6 Percent Increase in Facial Plastic Surgery in 2019; Millennials Report Early Maintenance for Social Media; Patient Priority is Safety

Resonetics announced today that it has begun improvements on a new 37,000 square foot facility in San Diego. The building is undergoing a complete renovation to meet Resonetics’ requirements.

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), announced today that Dr. Brian Poligone, clinical investigator and lead enroller in the pivotal Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study evaluating SGX301 in the treatment of early stage cutaneous T-cell lymphoma

Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), announced today that the Company has retained independent expert Joshua Mitts, a professor at Columbia University specializing in securities trading and the capital markets, to investigate recent past unusual trading activity in the Company’s common shares.